Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 29 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... May 12, 2020 Woman Died From Stage IV Breast Cancer After Doctor Misread Her... July 1, 2020 Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from... August 26, 2021 Pregnant Mom Experiencing Severe Leg And Back Pain Diagnosed With Stage... February 11, 2020 Load more HOT NEWS Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... Cancer in My Community: Caring for the Whole Patient in Brazil
